Brains Bioceutical Corp. (“Brains”) is pleased to announce the completion of its US$30m Capital Raise, including US$19m raised exclusively by Canaccord Genuity, and strategic partnership with a leading European Medical Cannabis Group. Brains’ founders and senior management participated with equity in the raise.

This sophisticated, sizeable and strategic transaction solidifies one of the largest partnerships operating in the Medical Cannabis sector in Europe.

Brains is a global leader in EUGMP- certified production of plant-based cannabidiol (CBD) as an Active Pharmaceutical Ingredient (API) for pharmaceutical and nutraceutical use.  Brains has already signed supply agreements with leading global pharmaceutical and health and wellness companies and commenced shipment to several countries around the world.

Brains is one of the few phyto-cannabinoid CBD API manufacturers in Europe with EudraGMDP certification currently in commercial production. Brains’ CBD API (its primary offering to the market) is MHRA licensed for both human and veterinary use and contains 99.7% CBD and zero Tetrahydrocannabinol (THC).  Part of the capital raised will be used to expand Brains’ existing UK CBD API production growing its current annual capacity from 864,000g to 6,912,000g per annum, a near seven-fold increase.

Brains’ CBD API is currently in use in a Phase III clinical trial for refractory epilepsy in adults conducted by a leading global pharmaceutical corporation.  Brains expects a positive outcome from this advanced clinical study and will be ramping up CBD API production to meet anticipated demand. Brains’ API has successfully been produced and shipped as a “Specials” medicine, approved by the MHRA, within the U.K.  The Brains team of skilled scientists and researchers are finalizing plans to create additional APIs for dominant cannabinoids including THC, CBG, CBN, CBC and more.

Q1 2020 will see Brains launch its branded nutraceutical CBD range of products in top tier health and wellness retail and pharmacy chains in the UK. All Brains’ products, own-brand and white-label, will bear the ‘Brains Inside®️’ trademark to provide the quality assurance stamp of EudraGMDP CBD API.

Brains is also well positioned to navigate the strict Novel Foods requirements in the UK from the Food Standards Association (FSA) and in Europe by the European Commission’s (EFSA) for CBD products.

Brains phyto-cannabinoid pure CBD API has successfully been tested by the INRS Laboratory, a World Anti-Doping Agency (WADA) facility. These screening reports have confirmed that Brains’ CBD API is free of THC, pesticides and other banned substances listed by WADA. Brains is first of its kind in the industry to get such a confirmation from a WADA- accredited laboratory for the purity of its CBD and the absence of prohibitory substances. WADA has removed CBD from its banned substance list.

The Brains partnership with a leading European Medical Cannabis Group creates a vertically integrated Medical Cannabis operation and has (via its subsidiaries) inter alia received in-principle approval from a European jurisdiction to obtain a license (to permit for the cultivation, extraction, processing, manufacture, storage, transport, import and export of medicinal cannabis and cannabis-derived products) and to establish a high-quality cannabinoid processing facility.